AMRI, Saneca Pharmaceuticals Partner for Opium-Derived APIsBy
AMRI, a contract research and manufacturing organization, and Saneca Pharmaceuticals, a supplier to the pharmaceutical industry, have formed a strategic collaboration focused on the development, manufacture, and marketing of a portfolio of opium-derived active pharmaceutical ingredients (APIs). The collaboration combines Saneca’s strength in extracting opiates from plant biomass and its expertise in developing and manufacturing controlled substance APIs with AMRI’s US assets and its expertise in technology transfer processes into these facilities. The collaboration will also capitalize on AMRI’s sales and marketing strength in the US market.
Under the collaboration, Saneca will supply intermediates, and where appropriate, process transfer technology to enable AMRI to develop more than two dozen APIs. Based on customer demand, AMRI will prepare the US regulatory filings, and following US Food and Drug Administration approval, will manufacture the APIs at its US Drug Enforcement Administration (DEA)-approved facilities. The companies will share revenue of any marketed APIs resulting from the collaboration. Additional details of the agreement were not disclosed.
Albany Molecular Research Inc. (AMRI) is a global contract research and manufacturing organization with locations in North America, Europe and Asia, Its key business segments include: Discovery and Development Solutions (DDS), Active Pharmaceutical Ingredients (API), and Drug Product Manufacturing (DPM). Saneca Pharmaceuticals is a supplier to the global pharmaceutical and healthcare industry. The company develops and produces pharmaceutical dosage forms, including solid, liquids, gels and creams. In addition, the company has portfolio of synthetic APIs and opiate APIs from plant biomass.